D.A. Davidson & CO. Has $375,000 Stake in Exact Sciences Corporation $EXAS

D.A. Davidson & CO. decreased its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 40.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,065 shares of the medical research company’s stock after selling 4,857 shares during the quarter. D.A. Davidson & CO.’s holdings in Exact Sciences were worth $375,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its stake in Exact Sciences by 2,804.8% in the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock valued at $26,000 after buying an additional 589 shares during the period. National Pension Service increased its holdings in shares of Exact Sciences by 75.1% in the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after acquiring an additional 292 shares in the last quarter. SVB Wealth LLC bought a new stake in shares of Exact Sciences in the first quarter worth about $30,000. Banque Cantonale Vaudoise bought a new stake in shares of Exact Sciences in the first quarter worth about $34,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Exact Sciences in the first quarter worth about $34,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insiders Place Their Bets

In other Exact Sciences news, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director directly owned 57,962 shares in the company, valued at $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wall Street Zen upgraded Exact Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. UBS Group lowered their price target on Exact Sciences from $61.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a report on Wednesday, October 8th. Piper Sandler increased their price objective on Exact Sciences from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada decreased their price objective on Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating for the company in a report on Thursday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.90.

Exact Sciences Stock Up 0.8%

EXAS stock opened at $63.22 on Friday. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. The business has a 50 day moving average price of $55.61 and a two-hundred day moving average price of $52.37. The company has a market cap of $11.97 billion, a price-to-earnings ratio of -11.64, a P/E/G ratio of 5.56 and a beta of 1.24. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $72.83.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.24. The firm had revenue of $811.09 million during the quarter, compared to the consensus estimate of $774.43 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business’s revenue was up 16.0% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. Analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.